Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide;Fatores e mecanismos envolvidos na hipertrofia ventricular esquerda e o papel anti-hipertrófico do óxido nítrico

Arquivos Brasileiros de Cardiologia

Volumn 90, Issue 6, 2008, Pages 443-450

  Garcia, José Antonio Dias ^a,c   Incerpi, Erika Kristina ^b  

^a Universidade José do Rosário Vellano UNIFENAS   (Brazil)

^b Universidade Vale do Rio Verde   (Brazil)

^c NONE   (Brazil)

Author keywords

Hypertrophy, left ventricular; Myocytes, cardiac; Nitric oxide

Indexed keywords

ANGIOTENSIN II; CATECHOLAMINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; INSULIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR;

ADRENERGIC SYSTEM; BLOOD PRESSURE; CELL PROLIFERATION; GENE EXPRESSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERCHOLESTEROLEMIA; HYPERVOLEMIA; OXIDATIVE STRESS; REVIEW;

EID: 46849096269     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008000600010     Document Type: Review

References (78)

1. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med. 1983; 3: 4-11.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000; 102: 470-9.
3. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999; 341: 1276-83.
4. Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension. 1996; 27: 14-8.
5. Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N, et al. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J. 2002; 66: 851-6.
6. Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocite hypertrophy and apoptosis. Heart Fail Rev. 2002; 7: 317-25.
7. Kempf T, Wollert KC. Nitric oxide and the enigma of cardiac hypertrophy. Bioessays. 2004; 6: 608-15.
8. Russell B, Motlagh D, Ashley WW. Form follows function: how muscle shape is regulated by work. J Appl Physiol. 2000; 88: 1127-32.
9. Pereira FEL. Hipertrofia cardíaca: aspectos morfológicos e patogenéticos. In Vassale DV, Lima EG (eds). Contratilidade miocárdica: aspectos básicos e clínicos. São Paulo: BYK, 1993. p. 13-28.
10. Morgan HE, Gordon EE, Kira Y, Chua BHL, Russo LA, Peterson CI, et al. Biochemical mechanisms of cardiac hypertrophy. Ann Rev Physiol. 1987; 49: 533-43.
11. Von Harsdorf R, Kang RE, Fullerton M, Woodcock EA. Myocardial stretch stimulates phosphatidyl-inositol turnover. Circ Res. 1989; 65: 494-501.
12. Sussman A, Mcculloch A, Borg TK. Dance band on the titanic: biomechanical signaling in cardiac hypertrophy. Circ Res. 2002; 91: 888-98.
13. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol. 1996; 12: 463-519.
14. Dash R, Schmidt AG, Pathak A, Gerst MJ, Biniakiewicz D, Kadambi VJ, et al. Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy. Cardiovasc Res. 2003; 57: 704-14.
15. Campos LA, Iliescu R, Fontes M, Schlegel WP, Bader M, Baltatu OC. Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen. Am J Physiol Heart Circ Physiol. 2006; 291 (5): H2371-6.
16. Shubeita HE, Martinson EA, Van Bilsen M, Chien KR, Brow JH. Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1992; 89: 1305-9.
17. Lindpaintner K , Ganten D. The cardiac rennin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991; 68 (1): 905-21.
18. Shirai H, Takahashi K, Katada T, Inagami T. Mapping of G protein coupling sites of the angiotensin II type 1 receptor. Hypertension. 1995; 25: 726-30.
19. Bernstein KE, Ali MS, Sayeski PP, Semeniuk D, Marrero MB. New insights into the cellular signaling of seven transmembrane receptors: the role of tyrosine phosphorylation. Lab Invest. 1998; 78: 3-7.
20. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993; 268 (33): 24539-42.
21. Senbonmatsu T, Ichihara S, Price E, Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000; 106: R25-R29.
22. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998; 97: 1952-9.
23. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414: 799-806.
24. Velloso LA, Carvalho CR, Rojas FA, Folli F, Saad MJ. Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2- growth related pathway. Cardiovasc Res. 1998; 40: 96-102.
25. Araujo EP, De Souza CT, Gasparetti AL, Ueno M, Boschero AC, Saad MJ, et al. Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance, hyperinsulinemia, and increased adiposity. Endocrinology. 2005; 146: 1428-37.
26. Zecchin HG, Carvalheira JBC, Saad MJA. Resistência à insulina, diabetes e hipertensão: bases fisiopatológicas. Rev Bras Hipertens. 2004; 11 (2): 124-7.
27. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105 (12): 1497-502.
28. Sykiotis GP, Papavassiliou AG. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol. 2001; 15: 1864-9.
29. Brownsey RW, Boone AN, Allard MF. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res. 1997; 34: 3-24.
30. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol. 2006; 291: H787-H796.
31. Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ. Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II. Circ Res. 2000; 86: 463-9.
32. Sato K, Komaru T, Shioiri H, Takeda S, Takahashi K, Kanatsuka H, et al. Hypercholesterolemia impairs transduction of vasodilator signals derived from ischemic myocardium: myocardium-microvessel cross-talk. Arterioscler Thromb Vasc Biol. 2004; 24 (11): 2034-9.
33. Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun. 2001; 289: 901-7.
34. Yao EH, Yu Y, Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr Pharm Biotechnol. 2006; 7: 101-8.
35. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1014-R1030.
36. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol. 2002; 40 (7): 1339-46.
37. Lee TM, Lin MS, Chou TF, Tasai CH, Chang NC. Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbits. Atherosclerosis. 2004; 176: 273-8.
38. Lee TM, Lin SM, Chou TF, Chang NC. Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol. 2005; 288: H1352-H1358.
39. Sugden P.H. Signaling pathways activated by vasoactive peptides in the cardiac myocytes and their role in the myocardial pathologies. J Card Fail. 2002; 8 (6): S359-69.
40. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res. 2005; 28 (6): 483-90.
41. Aubin MC, Carrier M, Shi YF, Tardif JC, Perrault LP. Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy. J Cardiovasc Pharmacol. 2006; 47 (5): 702-10.
42. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004; 38 (9): 1500-8.
43. Gelbmann CM, Leeb SN, Vogl D, Maendel M, Herfarth H, Scholmerich J, et al. Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut. 2003; 52 (10): 1448-56.
44. Vellaichamy E, Sommana NK, Pandey KN. Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem Biophys Res Commun. 2005; 327(1): 106-11.
45. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-95.
46. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: assembly of sarcomeric units in series VIA gp130/ leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996; 271: 9535-45.
47. Peng J, Gurantz D, Tran V, Cowling RT, Greenberg BH. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensina II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res. 2002; 91: 1119-26.
48. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100: 2153-7.
49. Balligand JL, Kobzik L, Han X, Kaye DM, Belhassen L, O'hara DS, et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem. 1995; 270: 14582-6.
50. Balligand J L, Cannon PJ. Nitric oxide synthases and cardiac muscle autocrine and paracrine influences. Arterioscler Thromb Vasc Biol. 1997; 17: 1846-58.
51. Schulz R, Smith JA, Lewis MJ, Moncada S. Nitric oxide synthase in cultured endocardial cells of the pig. Br J Pharmacol. 1991; 104: 21-4.
52. Klimaschewski L, Kummer W, Mayer B, Couraud JY, Preissler U, Philippin B, et al. Nitric oxide synthase in cardiac nerve fibers and neurons of rat and guinea pig heart. Circ Res. 1992; 71: 1533-7.
53. Tambascia RC, Fonseca PM, Corat PDC, Moreno H, Saad MJA, Franchini KG. Expression and distribution of NOS1 and NOS3 in the myocardium of angiotensin II infused rats. Hypertension. 2000; 37: 1423-8.
54. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999; 43 (3): 521-31.
55. Xu KY, Kuppusamy SP, Wang JQ, Li H, Cui H, Dawson TM, et al. Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation. J Biol Chem. 2003; 278 (43): 41798-803.
56. Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, et al. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005; 280 (22): 21594-9.
57. Ziolo MT, Bers DM.The real estate of NOS signaling: location, location, location. Circ Res. 2003; 92: 1279-81.
58. Barouch LA, Cappola TP, Harrison RW, Crone JK, Rodriguez ER, Burnett AL, et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol. 2003; 35: 637-44.
59. Fiedler B, Wollert KC. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res. 2004; 63 (3): 450-7.
60. Cheng TH, Shih NL, Chen SY, Lin JW, Chen YL, Chen CH, et al. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol. 2005; 68 (4): 1183-92.
61. Bush PK, Bartkova J, Strom CC, Wulf-Andersen L, Hinrichsen R, Christoffersen TE, et al. Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res. 2002; 56: 64-75.
62. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003; 93 (5): 388-98.
63. Hirata K, Nathanson MH, Burgstahler AD, Okazaki K, Mattei E, Sears ML. Relationship between inositol 1,4,5-trisphosphate receptor isoforms and subcellular Ca2+ signaling patterns in nonpigmented ciliary epithelia. Invest Ophthalmol Vis Sci. 1999; 40 (9): 2046-53.
64. Baker JE, Contney SJ, Singh R, Kalyanaraman B, Gross GJ, Bosnjak ZJ.Nitric oxide activates the sarcolemmal K(ATP) channel in normoxic and chronically hypoxic hearts by a cyclic GMP-dependent mechanism.J Mol Cell Cardiol. 2001;33 (2): 331-41.
65. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E, et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension. 2002; 39: 87-92.
66. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998; 82 (11): 1111-29.
67. Xie K, Huang S, Wang Y, Beltran PJ, Juang SH, Dong Z, et al. Bcl-2 protects cells from cytokine-induced nitric-oxide-dependent apoptosis. Cancer Immunol Immunother.1996; 43: 109-15.
68. Ing DJ, Zang J, Dzau VJ, Webster KA, Bishopric NH. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 1999; 84: 21-33.
69. Davies MG, Fulton GJ, Hagen PO. Clinical biology of nitric oxide. Br J Surg. 1995; 82: 1598-610.
70. Wong GKT, Marsdern PA. Nitric oxide synthases: regulation in disease. Nefron Dial transplant. 1996,11: 215-20.
71. Arstall MA, Sawyer DB, Fukazawa R, Kelly RA. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res. 1999; 85: 829-40.
72. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA. 1992; 89: 444-8.
73. Jaworski K, Kinard F, Goldstein D, Holvoet P, Trouet A, Schneider YJ, et al. S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells. Eur J Pharmacol. 2001; 425 (1): 11-9.
74. Ignarro J, Napoli C, loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Cir Res. 2002; 90: 21-8.
75. Taylor-McCabe KJ, Erasahin C, Simmons WH. Bradykinin metabolism in the isolated perfused rabbit heart. J Hypertens. 2001; 19: 1295-9.
76. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J. 1998; 19 (Suppl): J7-J15.
77. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK. Angiotensin II-mediated hypertension in the rate increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations in vasomotor tone. J Clin Invest. 1996; 97: 1916-23.
78. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992; 326: 90-4.